# OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis

> **NCT04375878** · PHASE2 · COMPLETED · sponsor: **Entero Therapeutics** · enrollment: 27 (actual)

## Conditions studied

- Exocrine Pancreatic Insufficiency (EPI)
- Cystic Fibrosis (CF)

## Interventions

- **DRUG:** MS1819
- **DRUG:** Porcine PERT

## Key facts

- **NCT ID:** NCT04375878
- **Lead sponsor:** Entero Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-20
- **Primary completion:** 2021-04-08
- **Final completion:** 2021-04-08
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2022-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04375878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04375878, "OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04375878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*